1. Home
  2. MIRM vs PAX Comparison

MIRM vs PAX Comparison

Compare MIRM & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • PAX
  • Stock Information
  • Founded
  • MIRM 2018
  • PAX 1988
  • Country
  • MIRM United States
  • PAX Cayman Islands
  • Employees
  • MIRM N/A
  • PAX N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • PAX Investment Managers
  • Sector
  • MIRM Health Care
  • PAX Finance
  • Exchange
  • MIRM Nasdaq
  • PAX Nasdaq
  • Market Cap
  • MIRM 2.2B
  • PAX 2.1B
  • IPO Year
  • MIRM 2019
  • PAX 2021
  • Fundamental
  • Price
  • MIRM $50.34
  • PAX $13.87
  • Analyst Decision
  • MIRM Strong Buy
  • PAX Strong Buy
  • Analyst Count
  • MIRM 12
  • PAX 1
  • Target Price
  • MIRM $63.17
  • PAX $14.00
  • AVG Volume (30 Days)
  • MIRM 397.8K
  • PAX 634.8K
  • Earning Date
  • MIRM 08-06-2025
  • PAX 07-31-2025
  • Dividend Yield
  • MIRM N/A
  • PAX 4.33%
  • EPS Growth
  • MIRM N/A
  • PAX N/A
  • EPS
  • MIRM N/A
  • PAX 0.45
  • Revenue
  • MIRM $379,251,000.00
  • PAX $389,900,000.00
  • Revenue This Year
  • MIRM $35.83
  • PAX $5.53
  • Revenue Next Year
  • MIRM $16.83
  • PAX N/A
  • P/E Ratio
  • MIRM N/A
  • PAX $30.58
  • Revenue Growth
  • MIRM 69.31
  • PAX 22.70
  • 52 Week Low
  • MIRM $28.56
  • PAX $9.43
  • 52 Week High
  • MIRM $54.23
  • PAX $14.12
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 69.78
  • PAX 66.42
  • Support Level
  • MIRM $48.78
  • PAX $13.65
  • Resistance Level
  • MIRM $50.05
  • PAX $14.02
  • Average True Range (ATR)
  • MIRM 1.64
  • PAX 0.28
  • MACD
  • MIRM 0.39
  • PAX -0.01
  • Stochastic Oscillator
  • MIRM 87.92
  • PAX 84.24

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About PAX Patria Investments Limited

Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.

Share on Social Networks: